Bayesian Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bayesian Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-38,922	Closed	-$700K	–	776
2020 Q2	$700K	Buy	+38,922	New	+$541K	0.15%	190
2020 Q1	–	Sell	-11,222	Closed	-$268K	–	1044
2019 Q4	$268K	Buy	+11,222	New	+$310K	0.05%	458
2019 Q2	–	Sell	-44,400	Closed	-$1.54M	–	744
2019 Q1	$1.54M	Buy	44,400 +14,500	+48%	+$418K	0.3%	102
2018 Q4	$584K	Buy	+29,900	New	+$615K	0.12%	247
2018 Q1	–	Sell	-7,961	Closed	-$388K	–	904
2017 Q4	$388K	Buy	+7,961	New	+$403K	0.08%	367
2017 Q3	–	Sell	-12,861	Closed	-$722K	–	704
2017 Q2	$722K	Buy	+12,861	New	+$515K	0.27%	130

Bayesian Capital Management's PTLA Position: Q3 2020 in Review

Bayesian Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 38,922 shares — an estimated $700K sold.

Bayesian Capital Management first reported a position in PTLA in Q2 2017 and held it in 6 quarters. The position peaked at $1.54M in Q1 2019. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

Bayesian Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Bayesian Capital Management sold 38,922 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $700K.
Bayesian Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2017 and held it in 6 quarters.
Bayesian Capital Management's Portola Pharmaceuticals, Inc. position peaked at $1.54M in Q1 2019.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Bayesian Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.